Erratum: The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: Results from the study on cognition and prognosis in the elderly (Journal of Human Hypertension (2005) vol. 19 (569-576) 10.1038/sj.jhh.1001857);The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: Results from the Study on COgnition and Prognosis in the Elderly

Journal of Human Hypertension

Volumn 19, Issue 7, 2005, Pages 569-576

  Lundkvist, Jonas ^a   Ekman, M ^a   Kartman, B ^b   Carlsson, J ^b   Jonsson L ^a   Lithell, H ^c  

^a STOCKHOLM HEALTH ECONOMICS   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Candesartan; Cost effectiveness; Cost utility; Elderly; Stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; PLACEBO;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FOLLOW UP; HOSPITAL PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; OUTPATIENT; PRIMARY PREVENTION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; STROKE;

EID: 21744455933     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001914     Document Type: Erratum

References (44)

1. Wester P et al. Slaganfall (Stroke). The Swedish Council on Technology Assessment in Health Care (SBU): Stockholm, 1992.
2. Causes of Death 2001. Centre for Epidemiology, The National Board of Health and Welfare: Stockholm, 2003.
3. Caird FI, Cargill D. Chronic brain failure: the silent epidemic. NZ Med J 1987; 100: 13-16.
4. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-1276.
5. Johannesson M, Jonsson B. Cost-effectiveness analysis of hypertension treatment - a review of methodological issues. Health Policy 1991; 19: 55-77.
6. Johannesson M. Economic evaluation of hypertension treatment. Int J Technol Assess Health Care 1992; 8: 506-523.
7. Strandgaard S, Paulson OB. Cerebrovascular consequences of hypertension. Lancet 1994; 344: 519-521.
8. Skoog I. Risk factors for vascular dementia: a review. Dementia 1994; 5: 137-144.
9. MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
10. Dahlof B et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285.
11. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
12. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-412.
13. Menard J. Cost-effectiveness of hypertension treatment. Clin Exp Hypertens 1996; 18: 399-413.
14. Johannesson M et al. The cost-effectiveness of treating hypertension in elderly people - an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Intern Med 1993; 234: 317-323.
15. Johannesson M. The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics 1995; 7: 242-250.
16. Degl'Innocenti A et al. Cognitive function and health-related quality of life in elderly patients with hypertension - baseline data from the study on cognition and prognosis in the elderly (SCOPE). Blood Press 2002; 11: 157-165.
17. Degl'Innocenti A et al. Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). J Hum Hypertens 2004; 18: 239-245.
18. Hansson L et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 1999; 8: 177-183.
19. Hansson L et al. Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics. Blood Press 2000; 9: 146-151.
20. Lithell H et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
21. Price indices. Statistical Yearbook of Sweden. Statistics Sweden: Stockholm, 2002.
22. Monthly and Yearly Average Exchange Rates Since 1980. Bank of Sweden: Stockholm, 2004.
23. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB (eds). Cost-effectiveness in Health and Medicine. Oxford University Press: New York (NY), 1996, pp 214-246.
24. Sonnenberg F, Beck J. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-338.
25. LINFO. FASS Läkemedel i Sverige (Swedish Drug Price List). Läkemedelsinformation AB: Oslo, 2002.
26. Kostnad per intagen patient [Cost per Admitted Patient]. Federation of county councils: Stockholm, 1996.
27. Wimo A, Sandman P. Demensvård för nästa sekel [Dementia care for the next century]. Report, Swedish Association of Local Authorities, 1999.
28. Regional hospital price lists. County councils in Sweden, 2002.
29. Meltzer D. Accounting for future costs in medical costeffectiveness analysis. J Health Econ 1997; 16: 33-64.
30. Johannesson M, Meltzer D, O'Conor RM. Incorporating future costs in medical cost-effectiveness analysis: Implications for the cost-effectiveness of treatment of hypertension. Med Decis Making 1997; 17: 382-389.
31. Ekman M, Zethraeus N, Dahlstrom U, Hoglund C. Kostnadseffektivt att behandla kronisk hjärtsvikt med bisoprolol [Cost-effectiveness of bisoprolol in chronic heart failure]. Lakartidningen 2002; 99: 646-650.
32. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQoL: results from a UK general population survey. Centre for Health Economics, University of York, 1997.
33. National Statistics. Statistic Sweden: Stockholm, 2003.
34. Bronnum-Hansen H, Davidsen M, Thorvaldsen P. Long-term survival and causes of death after stroke. Stroke 2001; 32: 2131-2136.
35. Lundberg L. Health-state utilities in a general population in relation to age, gender and socioeconomic factors. Eur J Publ Health 1999; 9: 211-217.
36. Newhouse JP. US and UK health economics: two disciplines separated by a common language? Health Econ 1998; 7: S79-S92.
37. Hirth RA, Chernew ME, Miller E. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-342.
38. Johannesson M, Meltzer D. Some reflections on costeffectiveness analysis. Health Econ 1998; 7: 1-7.
39. Ekman M. Studies in Health Economics. EFI, Stockholm School of Economics: Stockholm, 2002.
40. Zethraeus N, Molin T, Henriksson P, Jonsson B. Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med 1999; 246: 151-159.
41. Claesson L et al. Resource utilization and costs of stroke unit care integrated in a care continuum: A 1-year controlled, prospective, randomized study in elderly patients: the Goteborg 70+ Stroke Study. Stroke 2000; 31: 2569-2577.
42. Ghatnekar O, Persson U, Glader E, Terént A. The cost of stroke in Sweden - an incidence estimate. Int J Technol Assess Health Care 2004; 20: 375-380.
43. Burström K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001; 10: 621-635.
44. Ekman M. Economic evidence in stroke: a review. Eur J Health Econ 2004; 5(Suppl 1): S74-S83.